{"id":598113,"date":"2026-06-08T20:51:38","date_gmt":"2026-06-08T20:51:38","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/598113\/anal-fistula-market-trends-innovation-and-future-growth-outlook-to-2036-delveinsight-avobis-bio-therapeutics-stempeutics-research.html"},"modified":"2026-06-08T20:51:38","modified_gmt":"2026-06-08T20:51:38","slug":"anal-fistula-market-trends-innovation-and-future-growth-outlook-to-2036-delveinsight-avobis-bio-therapeutics-stempeutics-research","status":"publish","type":"post","link":"https:\/\/www.pennsylvania-magazine.com\/news\/story\/598113\/anal-fistula-market-trends-innovation-and-future-growth-outlook-to-2036-delveinsight-avobis-bio-therapeutics-stempeutics-research.html","title":{"rendered":"Anal Fistula Market Trends, Innovation, and Future Growth Outlook to 2036 &#8211; DelveInsight | Avobis Bio Therapeutics, Stempeutics Research"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1780944015.jpg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Anal Fistula Market Trends, Innovation, and Future Growth Outlook to 2036 - DelveInsight | Avobis Bio Therapeutics, Stempeutics Research \" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1780944015.jpg\" alt=\"Anal Fistula Market Trends, Innovation, and Future Growth Outlook to 2036 - DelveInsight | Avobis Bio Therapeutics, Stempeutics Research \" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">The Key Anal Fistula Companies in the market include &#8211; Avobis Bio Therapeutics, Stempeutics Research, and others.<\/div>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\">DelveInsight&rsquo;s <strong>&ldquo;Anal Fistula Market Insights, Epidemiology, and Market Forecast-2036&Prime;<\/strong> report offers an in-depth understanding of the Anal Fistula, historical and forecasted epidemiology as well as the Anal Fistula market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\">The latest healthcare forecast report provides an in-depth analysis of Anal Fistula, offering comprehensive insights into the Anal Fistula revenue trends, prevalence, and treatment landscape. The report delves into key Anal Fistula statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Anal Fistula therapies. Additionally, we cover the landscape of Anal Fistula clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Anal Fistula treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Anal Fistula space.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Get a Free sample for the Anal Fistula Market Forecast, Size &amp; Share Analysis Report: <\/strong><\/p>\n<p style=\"text-align: justify\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/anal-fistula-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/anal-fistula-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Some of the key facts of the Anal Fistula Market Report:<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">The Anal Fistula market size was valued at around <strong>USD 12 million in 2025<\/strong> and is anticipated to grow to nearly <strong>USD 120 million by 2036<\/strong>, registering a robust CAGR of 24% between 2026 and 2036.<\/p>\n<\/li>\n<li>\n<p><strong>In October 2025, Oncolytics Biotech<\/strong> announced updated clinical data for Pelareorep in combination with atezolizumab in previously treated metastatic Anal Fistula, demonstrating an objective response rate of ~30%, which was more than double historical response rates seen with currently available therapies.<\/p>\n<\/li>\n<li>\n<p><strong>In October 2025, Avobis Bio Therapeutics<\/strong> announced that the US FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AVB-114 for Crohn&rsquo;s perianal fistulas. The designation followed encouraging Phase II findings and strengthened regulatory interactions supporting future Phase III development planning.<\/p>\n<\/li>\n<li>\n<p><strong>In August 2025, Avobis Bio Therapeutics<\/strong> completed the primary analysis of the STOMP-II Phase II trial evaluating AVB-114 in Crohn&rsquo;s perianal fistulas. The company reported that the findings supported an RMAT submission and highlighted continued advancement of implantable regenerative therapies for complex fistulizing disease.<\/p>\n<\/li>\n<li>\n<p><strong>In August 2025, Invion Limited<\/strong> announced that the US FDA granted Orphan Drug Designation to INV043 for the treatment of Anal Fistula, providing incentives to support the development of this therapy for a rare disease.<\/p>\n<\/li>\n<li>\n<p><strong>In May 2025, Incyte<\/strong> announced that the FDA had approved ZYNYZ, making it the first and only approved first-line treatment for advanced Anal Fistula patients in the US. In addition, the FDA approved ZYNYZ as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.<\/p>\n<\/li>\n<li>\n<p><strong>In February 2025, Avobis Bio Therapeutics<\/strong> Fast Track Update announced that the US FDA granted Fast Track designation to AVB-114 for Crohn&rsquo;s perianal fistulas based on positive Phase I STOMP-I findings, reflecting increasing regulatory support for regenerative treatment approaches in refractory fistulizing disease.<\/p>\n<\/li>\n<li>\n<p>Chemoradiotherapy (CRT) remains the standard of care for localized Anal Fistula, with ongoing research focusing on targeted therapies, immunotherapies, and novel chemotherapeutic agents to improve treatment outcomes.<\/p>\n<\/li>\n<li>\n<p><strong>Nivolumab (OPDIVO) and pembrolizumab (KEYTRUDA)<\/strong> are considered second-line immunotherapy options for patients who do not respond to initial treatments.<\/p>\n<\/li>\n<li>\n<p>According to DelveInsight&rsquo;s estimates, in 2025, there were nearly 20,500 incident cases of Anal Fistula in the 7MM, out of which the US accounted for the highest incident cases in 2025.<\/p>\n<\/li>\n<li>\n<p>In EU4 and the UK, females accounted for more incident cases of Anal Fistula, i.e., nearly 70%, as compared to males with incident cases of nearly 30%, in 2025.<\/p>\n<\/li>\n<li>\n<p>In 2025, among EU4 and the UK, Germany accounted for the highest number of cases of Anal Fistula, whereas Spain accounted for the least number of cases.<\/p>\n<\/li>\n<li>\n<p>As per the analysis, in the United States in 2025, Anal Fistula was found to be more incident in patients aged 65 years and above (~60%), followed by patients aged 50-64 years (~37%), and it was lowest in patients below 50 years (~4%).<\/p>\n<\/li>\n<li>\n<p>In 2025, Japan accounted for approximately 1,200 incident cases of Anal Fistula accounted for approximately, which was significantly lower compared to the EU4 and the US.<\/p>\n<\/li>\n<li>\n<p>In Japan, HPV negative (~1, 100 cases) cases of Anal Fistula were found to be more incident than HPV positive (~100 cases) in 2025<\/p>\n<\/li>\n<li>\n<p><strong>Key Anal Fistula Companies:<\/strong> Avobis Bio Therapeutics, Stempeutics Research, and others.<\/p>\n<\/li>\n<li>\n<p><strong>Key Anal Fistula Therapies:<\/strong> AVB-114, Stempeucel, and others<\/p>\n<\/li>\n<li>\n<p>The epidemiology of Anal Fistula is segmented based on underlying etiologies and disease characteristics, including cryptoglandular fistulas, fistulas associated with Crohn&#8217;s Disease, recurrent fistulas, and complex fistulizing disease. The patient population is further categorized into diagnosed cases, fistula complexity-specific cases, recurrence-based populations, and treated patient pools across the 7MM.<\/p>\n<\/li>\n<li>\n<p>The prevalence of Anal Fistula continues to increase globally, primarily driven by rising incidence of anorectal abscesses, increasing prevalence of inflammatory bowel diseases, improved disease recognition, and expanding access to specialist colorectal care. Adults in younger and middle-aged populations represent a substantial proportion of affected patients.<\/p>\n<\/li>\n<li>\n<p>Male patients account for a larger proportion of the Anal Fistula population compared with females, with epidemiological studies consistently demonstrating a higher incidence among men, potentially due to differences in anorectal gland anatomy and disease susceptibility patterns.<\/p>\n<\/li>\n<li>\n<p>Anal fistula is a relatively uncommon but clinically significant anorectal disorder, with reported incidence ranging from approximately 1&ndash;8 cases per 10,000 individuals annually, contributing a substantial healthcare burden due to recurrence and need for repeated interventions.<\/p>\n<\/li>\n<li>\n<p>Anal fistula demonstrates a clear male predominance, with incidence estimates of approximately 12.3 per 100,000 in men versus 5.6 per 100,000 in women, indicating nearly a two-fold greater disease burden among males.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Anal Fistula Overview<\/strong><\/p>\n<p style=\"text-align: justify\">Anal Fistula is a rare type of cancer that develops in the tissues of the anus, the opening at the end of the rectum. It often begins in the squamous cells lining the anal canal. Risk factors include human papillomavirus (HPV) infection, smoking, weakened immune system, and a history of anal or genital warts. Symptoms may include bleeding, pain, itching, or a lump near the anus. Treatment options typically involve surgery, radiation therapy, and chemotherapy, depending on the stage and spread of the cancer. Early detection significantly improves outcomes.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>To Know in detail about the Anal Fistula market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anal-fistula-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Anal Fistula Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Anal Fistula Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Anal Fistula Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify\">The Anal Fistula market report proffers epidemiological analysis for the study period 2022&ndash;2036 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Total Diagnosed Prevalent Cases of Anal Fistula<\/p>\n<\/li>\n<li>\n<p>Gender-specific Diagnosed Prevalent Cases of Anal Fistula<\/p>\n<\/li>\n<li>\n<p>Age-specific Diagnosed Prevalent Cases of Anal Fistula<\/p>\n<\/li>\n<li>\n<p>Type-specific Diagnosed Prevalent Cases of Anal Fistula<\/p>\n<\/li>\n<li>\n<p>Treated Cases of Anal Fistula<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Download the report to understand which factors are driving Anal Fistula epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anal-fistula-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Anal Fistula Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Anal Fistula Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Anal Fistula market or expected to get launched during the study period. The analysis covers Anal Fistula market uptake by drugs, patient uptake by therapies, and sales of each drug.<\/p>\n<p style=\"text-align: justify\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify\">The report also covers the Anal Fistula Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Anal Fistula Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p><strong>AVB-114:<\/strong> Avobis Bio Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>Stempeucel:<\/strong> Stempeutics Research<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Discover more about therapies set to grab major Anal Fistula market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anal-fistula-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Anal Fistula Treatment Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Anal Fistula Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Increasing incidence of HPV-associated Anal Fistula, particularly among high-risk populations, is driving demand for effective treatment options.<\/p>\n<\/li>\n<li>\n<p>Growing awareness and improved screening practices are facilitating earlier diagnosis and increasing the number of patients entering treatment pathways.<\/p>\n<\/li>\n<li>\n<p>Advancements in immunotherapy and targeted therapies are expanding treatment options for advanced and recurrent Anal Fistula.<\/p>\n<\/li>\n<li>\n<p>Rising investment in oncology research and clinical trials is accelerating the development of novel therapeutics for Anal Fistula.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Anal Fistula Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Relatively low disease prevalence compared to other cancers limits patient populations and may reduce commercial incentives for drug development.<\/p>\n<\/li>\n<li>\n<p>Limited availability of approved targeted therapies restricts treatment choices, particularly for advanced or metastatic disease.<\/p>\n<\/li>\n<li>\n<p>Challenges in early detection and diagnosis can lead to delayed treatment and poorer clinical outcomes.<\/p>\n<\/li>\n<li>\n<p>High treatment costs and reimbursement constraints may hinder access to novel therapies in certain regions.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Scope of the Anal Fistula Market Report<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p><strong>Study Period: 2022&ndash;2036<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/p>\n<\/li>\n<li>\n<p><strong>Key Anal Fistula Companies:<\/strong> Avobis Bio Therapeutics, Stempeutics Research, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Anal Fistula Therapies:<\/strong> AVB-114, Stempeucel, and others<\/p>\n<\/li>\n<li>\n<p><strong>Anal Fistula Therapeutic Assessment:<\/strong> Anal Fistula current marketed and Anal Fistula emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Anal Fistula Market Dynamics:<\/strong> Anal Fistula market drivers and Anal Fistula market barriers<\/p>\n<\/li>\n<li>\n<p><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/p>\n<\/li>\n<li>\n<p><strong>Anal Fistula Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Anal Fistula Market Access and Reimbursement <\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>To know more about Anal Fistula companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anal-fistula-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Anal Fistula Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Table of Contents <\/strong><\/p>\n<p style=\"text-align: justify\">1. Anal Fistula Market Report Introduction<\/p>\n<p style=\"text-align: justify\">2. Executive Summary for Anal Fistula<\/p>\n<p style=\"text-align: justify\">3. SWOT analysis of Anal Fistula<\/p>\n<p style=\"text-align: justify\">4. Anal Fistula Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify\">5. Anal Fistula Market Overview at a Glance<\/p>\n<p style=\"text-align: justify\">6. Anal Fistula Disease Background and Overview<\/p>\n<p style=\"text-align: justify\">7. Anal Fistula Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify\">8. Country-Specific Patient Population of Anal Fistula<\/p>\n<p style=\"text-align: justify\">9. Anal Fistula Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify\">10. Anal Fistula Unmet Needs<\/p>\n<p style=\"text-align: justify\">11. Anal Fistula Emerging Therapies<\/p>\n<p style=\"text-align: justify\">12. Anal Fistula Market Outlook<\/p>\n<p style=\"text-align: justify\">13. Country-Wise Anal Fistula Market Analysis (2022&ndash;2036)<\/p>\n<p style=\"text-align: justify\">14. Anal Fistula Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify\">15. Anal Fistula Market Drivers<\/p>\n<p style=\"text-align: justify\">16. Anal Fistula Market Barriers<\/p>\n<p style=\"text-align: justify\">17. Anal Fistula Appendix<\/p>\n<p style=\"text-align: justify\">18. Anal Fistula Report Methodology<\/p>\n<p style=\"text-align: justify\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify\">20. Disclaimer<\/p>\n<p style=\"text-align: justify\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>About DelveInsight <\/strong><\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_72253.html\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=anal-fistula-market-trends-innovation-and-future-growth-outlook-to-2036-delveinsight-avobis-bio-therapeutics-stempeutics-research\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679 <br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=anal-fistula-market-trends-innovation-and-future-growth-outlook-to-2036-delveinsight-avobis-bio-therapeutics-stempeutics-research\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Key Anal Fistula Companies in the market include &#8211; Avobis Bio Therapeutics, Stempeutics Research, and others. &nbsp; DelveInsight&rsquo;s &ldquo;Anal Fistula Market Insights, Epidemiology, and Market Forecast-2036&Prime; report offers an<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts\/598113"}],"collection":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/comments?post=598113"}],"version-history":[{"count":0,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts\/598113\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/media?parent=598113"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/categories?post=598113"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/tags?post=598113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}